UNIVERSITY OF WATERLOO

AI is transforming drug development by 2025, streamlining processes and opening new possibilities, particularly in clinical trials. Unlearn's AI-driven digital twin technology optimises trials, reducing costs and speeding recruitment. Despite initial distrust and communication gaps, the industry is embracing AI's potential to revolutionise pharma, with significant advancements expected in rare diseases by 2025.

39 million people live with HIV, 630,000 died in 2022, and 1.3 million acquired the disease. UNAIDS aims to end HIV/AIDS by 2030. Challenges include HIV's ability to integrate into host genomes, forming latent reservoirs, and global disparities in treatment access. Innovative strategies like Dr. Ho's nanomedicine targeting CCR5 and Nef aim to prevent and treat HIV. Dr. Mann's HIV-like particles (HLP) reactivate dormant HIV for cART and immune system targeting, moving towards clinical trials for a potential cure.

New nanomedicine from University of Waterloo encapsulates entire antibiotic course, releasing drugs only in presence of bacterial toxins, potentially reducing side effects and antimicrobial resistance.

University of Waterloo researchers developed a nanomedicine that holds an entire course of antibiotics in one dose, delivering the exact amount needed to fight infections like meningitis and bacterial vaginosis, reducing antibiotic resistance and side effects.

University of Waterloo researchers developed a nanomedicine that holds an entire course of antibiotics in one tiny dose, delivering the exact amount needed to fight infections like meningitis and bacterial vaginosis, reducing antibiotic resistance and side effects.

Rupi Kaur, a poet-celebrity, reflects on her journey since self-publishing 'Milk and Honey' in 2014, her influence on poetry's accessibility, and her impact on inspiring others to write and publish their work.